Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1727344 | 0.81 | APP (0.62) | MAPTKDM4ESMN1; SMN2RAB9AMEN1 | |
| SCHEMBL5776840 | 0.76 | RAB9A (0.57) | MAPTKDM4ESMN1; SMN2RAB9AMEN1 | |
| SCHEMBL1726397 | 0.76 | RAB9A (0.46) | MAPTKDM4ESMN1; SMN2RAB9AMEN1 | |
| SCHEMBL14076028 | 0.75 | KDM4E (0.57) | MAPTKDM4ESMN1; SMN2RAB9AMEN1 | |
| SCHEMBL796015 | 0.74 | APP (0.59) | KDM4ESMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL17626893 | 0.72 | MAPT (0.44) | MAPTKDM4ESMN1; SMN2RAB9AMEN1 | |
| SCHEMBL14076026 | 0.72 | APP (0.71) | MAPTKDM4ESMN1; SMN2RAB9AAPP | |
| SCHEMBL13411203 | 0.72 | HRH3 (0.70) | MAPTKDM4ESMN1; SMN2RAB9AMEN1 | |
| SCHEMBL3303704 | 0.72 | NPC1 (0.74) | MAPTKDM4ESMN1; SMN2RAB9AMEN1 | |
| SCHEMBL1725963 | 0.71 | HRH3 (0.69) | MAPTKDM4ESMN1; SMN2RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8506930-B2 | Compounds having affinity for amyloid | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8506930-B2 | Compounds having affinity for amyloid | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8303935-B2 | Alkoxy substituted imidazo[1,2-a]pyridines having affinity for amyloid | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20120271053-A1 | NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120271053-A1 | NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2012-10-25 | — | — | US | disclosed |
| WO-2011029443-A8 | DEVICE FOR A MULTIPLE SOCKET FOR RECEIVING PLUG CONNECTIONS | HOHENADEL THORSTEN (DE) | 2012-05-10 | — | — | WO | disclosed |
| EP-2019103-B1 | COMPOUND HAVING AFFINITY FOR AMYLOID | NIHON MEDIPHYSICS CO LTD (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-20100267952-A1 | USE OF NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID, AND PROCESS FOR PRODUCTION OF THE SAME | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2218463-A1 | USE OF NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID, AND PROCESS FOR PRODUCTION OF THE SAME | Nihon Medi-Physics Co., Ltd. (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-20090252679-A1 | Novel Compound Having Affinity for Amyloid | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-2019103-A1 | NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2009-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090252679-A1 | Novel Compound Having Affinity for Amyloid | APBA1, SAAL1, SLC43A1 | MAPT 334/4885KDM4E 4742/4885SMN1; SMN2 684/4885 |
| US-20100267952-A1 | USE OF NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID, AND PROCESS FOR PRODUCTION OF THE SAME | APBA1, APP, SAAL1 | MAPT 660/4885KDM4E 4685/4885SMN1; SMN2 835/4885 |
| US-20120271053-A1 | NOVEL COMPOUND HAVING AFFINITY FOR AMYLOID | APBA1, SAAL1, SLC43A1 | MAPT 334/4885KDM4E 4742/4885SMN1; SMN2 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.